Obesity, Morbid
Conditions
Keywords
bariatric surgery, asprosin
Brief summary
the present study aimed to systematically assess the changes in plasma asprosin levels at 3, 6, and 12 months after LSG, to explore the relationships between asprosin dynamics and key metabolic parameters, including body mass index (BMI), fasting glucose, insulin resistance assessed by the homeostasis model (HOMA-IR), and lipid profiles, and to compare asprosin concentrations between bariatric patients and healthy normal-weight controls.
Interventions
PROCEDUREsurgery
laparoscopic sleeve gastrectomy
Sponsors
Northern Jiangsu People's Hospital
Study design
Observational model
CASE_CROSSOVER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
1. age between 18 and 65 years; 2. body mass index (BMI) ≥37.5 kg/m², or BMI ≥32.5 kg/m² with at least one obesity-related comorbidity; 3. availability of complete clinical data and stored plasma samples at preoperative baseline and at 3, 6, and 12 months postoperatively.
Exclusion criteria
1. history of prior bariatric or gastrointestinal surgery; 2. active malignancy, chronic inflammatory or infectious disease, or severe hepatic or renal dysfunction; 3. pregnancy during the study period; 4. incomplete clinical or biochemical data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma asprosin levels at 3, 6, and 12 months | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| BMI at 3, 6, and 12 months | 1 year |
Other
| Measure | Time frame |
|---|---|
| Insulin resistance (HOMA-IR) at 3, 6, and 12 months | 1 year |
Countries
China
Outcome results
None listed